Benoît Mâsse, Ph.D., is an associate member of the Statistical Center for HIV/AIDS Research & Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center at the Fred Hutchinson Cancer Research Center in Seattle, Washington, and affiliate associate professor in the department of biostatistics at the University of Washington School of Public Health and Community Medicine. For the Microbicide Trials Network (MTN), Dr. Mâsse is principal investigator for the Statistical and Data Management Center (SDMC), overseeing statistical design, data management study oversight and data analysis – functions that are critical to the successful implementation of MTN's broad portfolio of HIV prevention trials.
As a member of the SCHARP Executive Leadership Group, Dr. Mâsse is involved in oversight of SDMCs of other National Institute of Allergy and Infectious Diseases (NIAID)-sponsored networks, such as the HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) as well as for large NIAID-funded projects such as the Center for HIV-AIDS Vaccine Immunology, or CHAVI. Dr. Mâsse has significantly contributed to the design of several other HIV microbicide and prevention research trials, including preparedness studies, safety studies (Phase I and II), and efficacy trials (Phase IIB and III). He has served as lead statistician on HPTN 035 (Phase II/IIB), HPTN 050 (Phase I), HPTN 052 (Phase III), HPTN 055 (preparedness), HPTN 059 (Phase II) and COL-1492 (Phase II/III). He was also a co-investigator and the lead statistician on the OMEGA cohort study involving gay men in Montréal and principal investigator for the SDMC of the COL-1492 trial. Much of Dr. Mâsse's research has focused on developing methods for analysis of infectious diseases data, developing mathematical models of infectious disease transmission and validating trial designs using mathematical models. He currently is co-investigator of a study funded by the Centers for AIDS Research at NIAID that is undertaking the development of models for HIV prevention efficacy trials. He has conducted similar work aimed at improving design and precision of Phase III HIV vaccine efficacy trials.
Dr. Mâsse has contributed to some 40 research grants since 1993. In addition to studies focused on HIV/AIDS, Dr. Mâsse has been involved in clinical trials on head and neck cancer chemoprevention; studies of breast cancer and breast density; and psychosocial and work environment studies on cardiovascular diseases, urinary infection, delirium in cancer palliative care, and pain management in early termination of pregnancy. An author of nearly 100 peer-reviewed articles, Dr. Mâsse has served as a voting member on the Clinical Trials Grant Committee for both the National Cancer Institute of Canada (1995-98) and the Canadian Institutes of Health Research (2000-2006). Dr. Mâsse joined SCHARP in 2000 from Laval University in Quebec City, where he was an associate professor in the department of social and preventive medicine, an adjunct professor in the department of mathematics and statistics, and director, Service of Methodological Support for Clinical Research at the Laval University Affiliated Research Hospital. He received a bachelor of science in mathematics and a master of science in statistics from the University of Montréal and earned a Ph.D. in biostatistics at the School of Public Health, University of North Carolina at Chapel Hill.